Noninferiority trial comparing a first-generation cephalosporin with a third-generation cephalosporin in the treatment of nonsevere clinical mastitis in dairy cows

Journal of Dairy Science

Volumn 96, Issue 10, 2013, Pages 6763-6774

  Schukken, Y H ^a   Zurakowski, M J ^a   Rauch, B J ^a   Gross, B ^a   Tikofsky, L L ^b   Welcome, F L ^a  

^a Department of Molecular Biology and Genetics   (United States)

^b BOEHRINGER INGELHEIM VETMEDICA INC   (United States)

Author keywords

Cephapirin; Clinical trial; Mastitis; Noninferiority

Indexed keywords

BACTERIA (MICROORGANISMS); BOS; ESCHERICHIA COLI; KLEBSIELLA; NEGIBACTERIA; POSIBACTERIA; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS UBERIS;

ANTIINFECTIVE AGENT; CEFAPIRIN; CEFTIOFUR; CEPHALOSPORIN DERIVATIVE;

ANIMAL; BACTERIA; BOVINAE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; ISOLATION AND PURIFICATION; MASTITIS, BOVINE; MICROBIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; CATTLE; CEPHALOSPORINS; CEPHAPIRIN; FEMALE; MASTITIS, BOVINE;

EID: 84884349593     PISSN: 00220302     EISSN: 15253198     Source Type: Journal    
DOI: 10.3168/jds.2013-6713     Document Type: Article

References (35)

1. Apparao M.D., Ruegg P.L., Lago A., Godden S., Bey R., Leslie K. Relationship between in vitro susceptibility test results and treatment outcomes for gram-positive mastitis pathogens following treatment with cephapirin sodium. J. Dairy Sci. 2009, 92:2589-2597.
2. Barkema H.W., Schukken Y.H., Lam T.J.G.M., Beiboer M.L., Wilmink H., Benedictus G., Brand A. Incidence of clinical mastitis in dairy herds grouped in three categories by bulk milk somatic cell counts. J. Dairy Sci. 1998, 81:411-419.
3. Bengtsson B., Unnerstad H.E., Ekman T., Artursson K., Nilsson-Ost M., Waller K.P. Antimicrobial susceptibility of udder pathogens from cases of acute clinical mastitis in dairy cows. Vet. Microbiol. 2009, 136:142-149.
4. Bradley A.J., Green M.J. Factors affecting cure when treating bovine clinical mastitis with cephalosporin-based intramammary preparations. J. Dairy Sci. 2009, 92:1941-1953.
5. Deluyker H.A., Chester S.T., Van Oye S.N. A multilocation clinical trial in lactating dairy cows affected with clinical mastitis to compare the efficacy of treatment with intramammary infusions of a lincomycin/neomycin combination with an ampicillin/cloxacillin combination. J. Vet. Pharmacol. Ther. 1999, 22:274-282.
6. Erskine R.J., Bartlett P.C., VanLente J.L., Phipps C.R. Efficacy of systemic ceftiofur as a therapy for severe clinical mastitis in dairy cattle. J. Dairy Sci. 2002, 85:2571-2575.
7. Erskine R.J., Eberhart R.J., Hutchinson L.J., Spencer S.B., Campbell M.A. Incidence and types of clinical mastitis in dairy herds with high and low somatic cell counts. J. Am. Vet. Med. Assoc. 1988, 192:761-765.
8. European Medicines Agency. 2009. EMEA/CVP/344/99: Guideline for the conduct of efficacy studies for intramammary products for use in cattle. Accessed Jul. 26, 2013. http://http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004501.pdf.
9. Gorden P.J., van der List M., Lehman F.D., Lantz R.K., Constable P.D. Elimination kinetics of cephapirin sodium in milk after an 8-day extended therapy program of daily intramammary infusion in healthy lactating Holstein-Friesian cows. J. Dairy Sci. 2013, 96:4455-4464.
10. Gröhn Y.T., Wilson D.J., González R.N., Hertl J.A., Schulte H., Bennett G., Schukken Y.H. Effect of pathogen-specific clinical mastitis on milk yield in dairy cows. J. Dairy Sci. 2004, 87:3358-3374.
11. Guérin-Faublée V., Carret G., Houffschmitt P. In vitro activity of 10 antimicrobial agents against bacteria isolated from cows with clinical mastitis. Vet. Rec. 2003, 152:466-471.
12. Hornish R.E., Kotarski S.F. Cephalosporins in veterinary medicine-Ceftiofur use in food animals. Curr. Top. Med. Chem. 2002, 2:717-731.
13. Lago A., Godden S.M., Bey R., Ruegg P.L., Leslie K. The selective treatment of clinical mastitis based on on-farm culture results: I. Effects on antibiotic use, milk withholding time, and short-term clinical and bacteriologic outcomes. J. Dairy Sci. 2010, 94:4441-4456.
14. McDougall S. A randomised, non-inferiority trial of a new cephalonium dry-cow therapy. N. Z. Vet. J. 2010, 58:45-58.
15. McDougall S., Arthur D.G., Bryan M.A., Vermunt J.J., Weir A.M. Clinical and bacteriological response to treatment of clinical mastitis with one of three intramammary antibiotics. N. Z. Vet. J. 2007, 55:161-170.
16. Laboratory Handbook on Bovine Mastitis 1999, National Mastitis Council, National Mastitis Council, Madison, WI.
17. O'Connor A.M., Sargeant J.M., Gardner I.A., Dickson J.S., Torrence M.E., Dewey C.E., Dohoo I.R., Evans R.B., Gray J.T., Greiner M., Keefe G., Lefebvre S.L., Morley P.S., Ramirez A., Sischo W., Smith D.R., Snedeker K., Sofos J., Buchanan R.L., Dickson J.S., Evans R.B., Fergen B., Gardner I.A., Gray J.T., Greiner M., Keefe G., Lechtenberg K., Lefebvre S.L., Morley P.S., Ramirez A., Rauch B.J., Read S.C., Sischo W., Smith D.R., Snedeker K., Sofos J.N., Ward M.P., Wills R.W. The REFLECT statement: Methods and processes of creating reporting guidelines for randomized controlled trials for livestock and food safety by modifying the CONSORT statement. Zoonoses Public Health 2010, 57:95-104.
18. Olde Riekerink R.G., Barkema H.W., Kelton D.F., Scholl D.T. Incidence rate of clinical mastitis on Canadian dairy farms. J. Dairy Sci. 2008, 91:1366-1377.
19. Pfeifer Y., Cullik A., Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int. J. Med. Microbiol. 2010, 300:371-379.
20. Piaggio G., Elbourne D.R., Altman D.G., Pocock S.J., Evans S.J.W. Reporting of non-inferiority and equivalence randomized trials: An extension of the CONSORT statement. JAMA 2006, 295:1152-1160.
21. Powers J.H. Non-inferiority and equivalence trials: Deciphering similarity of medical interventions. Stat. Med. 2008, 27:343-352.
22. Pyörälä S., Kaartinen L., Käck H., Rainio V. Efficacy of two therapy regimens for treatment of experimentally induced Escherichia coli mastitis in cows. J. Dairy Sci. 1994, 77:453-461.
23. Roberson J.R. Treatment of clinical mastitis. Vet. Clin. North Am. Food Anim. Pract. 2012, 28:271-288.
24. Roberson J.R., Warnick L.D., Moore G. Mild to moderate clinical mastitis: Efficacy of intramammary amoxicillin, frequent milk-out, a combined intramammary amoxicillin, and frequent milk-out treatment versus no treatment. J. Dairy Sci. 2004, 87:583-592.
25. SAS software. Version 9.2 2009, SAS Institute, SAS Institute Inc., Cary, NC.
26. Schukken Y.H., Bennett G.J., Zurakowski M.J., Sharkey H.L., Rauch B.J., Thomas M.J., Ceglowski B., Saltman R.L., Belomestnykh N., Zadoks R.N. Randomized clinical trial to evaluate the efficacy of a 5-day ceftiofur hydrochloride intramammary treatment on nonsevere gram-negative clinical mastitis. J. Dairy Sci. 2011, 94:6203-6215.
27. Schukken Y.H., Deluyker H.A. Design of field trials for the evaluation of antibacterial products for therapy of bovine clinical mastitis. J. Vet. Pharmacol. Ther. 1995, 18:274-283.
28. Reflection paper on the use of third and fourth generation cephalosporins in food producing animals in the European Union: Development of resistance and impact on human and animal health. J. Vet. Pharmacol. Ther. 2009, 32:515-533. Scientific Advisory Group on Antimicrobials of the Committee for Medicinal Products for Veterinary Use.
29. Steeneveld W., van Werven T., Barkema H.W., Hogeveen H. Cow-specific treatment of clinical mastitis: An economic approach. J. Dairy Sci. 2011, 94:174-188.
30. Taponen S., Dredge K., Henriksson B., Pyyhtiä A.M., Suojala L., Junni R., Heinonen K., Pyörälä S. Efficacy of intramammary treatment with procaine penicillin G vs. procaine penicillin G plus neomycin in bovine clinical mastitis caused by penicillin-susceptible, gram-positive bacteria-A double blind field study. J. Vet. Pharmacol. Ther. 2003, 26:193-198.
31. US FDA-CVM (Food and Drug Administration Center for Veterinary Medicine). 1996. CVM Guidance for Industry #49: Target animal safety and drug effectiveness studies for anti-microbial bovine mastitis products (lactating and non-lactating cow products). Accessed Jul. 26, 2013. http://http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm053411.htm.
32. Waage S. Comparison of two regimens for the treatment of clinical bovine mastitis caused by bacteria sensitive to penicillin. Vet. Rec. 1997, 141:616-620.
33. Wenz J.R., Barrington G.M., Garry F.B., Dinsmore R.P., Callan R.J. Use of systemic disease signs to assess disease severity in dairy cows with acute coliform mastitis. J. Am. Vet. Med. Assoc. 2001, 218:567-572.
34. Wenz J.R., Garry F.B., Barrington G.M. Comparison of disease severity scoring systems for dairy cattle with acute coliform mastitis. J. Am. Vet. Med. Assoc. 2006, 229:259-262.
35. Wenz J.R., Garry F.B., Lombard J.E., Elia R., Prentice D., Dinsmore R.P. Efficacy of parenteral ceftiofur for treatment of systemically mild clinical mastitis in dairy cattle. J. Dairy Sci. 2005, 88:3496-3499.